Pharma Leaders Confront Another Daunting Challenge: Meeting COVID-19 Demand
Executive Summary
Pharma leaders at the CNBC Healthy Returns virtual conference said they are optimistic industry will deliver a SARS-COV-2 vaccine, but ramping up the supply will require time and collaboration.
You may also be interested in...
Remdesivir Distribution Begins With More Questions Than Answers
Ethicists decry the government's opaque approach, highlighting the potential risks of a fast US FDA emergency authorization if supply isn't able to support demand following regulatory clearance. AmerisourceBergen is distributing the drug for the government, but within the Administration, no agency appears to want to take public responsibility for the decisions about where the doses of the COVID-19 treatment are sent.
Moderna’s COVID-19 Vaccine To Move Faster Into Phase III
mRNA company confident as it heads towards Phase II trials, but says efficacy and approval will not be a ‘binary event’.
Regeneron Maintains Its Momentum During Pandemic
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.